GeoVax Labs is a biotechnology business based in the US. GeoVax Labs shares (GOVX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.61 – a decrease of 3.33% over the previous week. GeoVax Labs employs 17 staff and has a trailing 12-month revenue of around $300,677.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.61 |
|---|---|
| 52-week range | $1.09 - $11.18 |
| 50-day moving average | $2.42 |
| 200-day moving average | $2.45 |
| Wall St. target price | $14.20 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-12.87 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.91 from 2024-11-19
| 1 week (2024-11-13) | 7.78% |
|---|---|
| 1 month (2024-10-18) | 37.26% |
| 3 months (2024-08-20) | -48.77% |
| 6 months (2024-05-20) | 78.53% |
| 1 year (2023-11-20) | 445.97% |
|---|---|
| 2 years (2022-11-18) | -75.37% |
| 3 years (2021-11-19) | 60.45 |
| 5 years (2019-11-20) | 420 |
| Revenue TTM | $300,677 |
|---|---|
| Gross profit TTM | $81,526 |
| Return on assets TTM | -134.35% |
| Return on equity TTM | -362.39% |
| Profit margin | 0% |
| Book value | $2.92 |
| Market Capitalization | $22.2 million |
TTM: trailing 12 months
We're not expecting GeoVax Labs to pay a dividend over the next 12 months.
You may also wish to consider:
GeoVax Labs's shares were split on a 1:15 basis on 30 January 2024 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your GeoVax Labs shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for GeoVax Labs shares which in turn could have impacted GeoVax Labs's share price.
Over the last 12 months, GeoVax Labs's shares have ranged in value from as little as $1.0901 up to $11.18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while GeoVax Labs's is 3.109. This would suggest that GeoVax Labs's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put GeoVax Labs's beta into context you can compare it against those of similar companies.
GeoVax Labs, Inc. , a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U. S.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.